亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AAPG 亚盛医药

盘前交易 09-04 05:25:02 EDT

17.36

+0.55

+3.27%

盘前17.37

+0.01+0.06%

04:12 EDT

最高17.59	最低17.20	成交量1.01万
今开17.58	昨收16.81	日振幅2.32%
总市值16.20亿	流通市值12.43亿	总股本9,333万
成交额17.41万	换手率0.01%	流通股本7,158万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":17.36,"timestamp":1788465600000,"preClose":16.81,"halted":0,"volume":10093,"hourTrading":{"tag":"盘前","latestPrice":17.37,"preClose":17.36,"latestTime":"04:12 EDT","volume":1961,"amount":34105.109973,"timestamp":1788509551728,"change":0.01,"changeRate":0.000576,"amplitude":0.001728},"delay":0,"changeRate":0.03271861986912557,"floatShares":71582800,"shares":93330405,"eps":-2.325979,"marketStatus":"盘前交易","change":0.55,"latestTime":"09-04 05:25:02 EDT","open":17.58,"high":17.59,"low":17.2,"amount":174101.403774,"amplitude":0.0232,"askPrice":25,"askSize":1000,"bidPrice":14.53,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.325979,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":17.36,"preHourTrading":{"tag":"盘前","latestPrice":17.37,"preClose":17.36,"latestTime":"04:12 EDT","volume":1961,"amount":34105.109973,"timestamp":1788509551728,"change":0.01,"changeRate":0.000576,"amplitude":0.001728},"postHourTrading":{"tag":"盘后","latestPrice":17.5,"preClose":17.36,"latestTime":"19:30 EDT","volume":330,"amount":5776.12,"timestamp":1788478205811,"change":0.14,"changeRate":0.008065,"amplitude":0.008065},"volumeRatio":1.342832793015096},"requestUrl":"/m/hq/s/AAPG","defaultTab":"news","newsList":[{"id":"2660347943","title":"亚盛医药(06855)公布2026年中期业绩：商业化造血能力持续提升，全球化进程加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2660347943","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660347943?lang=zh_cn&edition=full","pubTime":"2026-08-20 07:36","pubTimestamp":1787182583,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，亚盛医药今日公布2026年中期业绩。2026年上半年，公司实现总收入3.02亿元人民币，同比增长29%。在耐立克与利生妥两大商业化产品的双引擎驱动下，公司自我造血能力持续加强。报告期内，公司产品销售收入达到人民币2.82亿元，同比增长33%。截至报告期末，公司总货币资金约19亿元人民币，资金储备充足，为全球研发与商业化拓展提供坚实支撑。亚盛医药正全面快速推进这些全球注册III期临床研究，全球创新将迎来收获期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK4139","AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168288","title":"亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168288","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168288?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:13","pubTimestamp":1786626780,"startTime":"0","endTime":"0","summary":"中国苏州2026年8月13日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司管理层将出席于2026年8月17日-19日在上海浦东丽思卡尔顿酒店举办的Evercore第二届中国生物科技峰会。会议期间，公司管理层将参与由Evercore研究团队主持的炉边谈话，并开展一对一投资者交流会。因此，该等前瞻性陈述不应被视为对未来事件的预测。无论出现新信息、未来事件或其他情况，亚盛医药均无义务更新或修订任何前瞻性陈述。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","EVR","KURE","BK1161","BK4127","AAPG","06855","BK1574","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181890937","title":"财报前瞻 ｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1181890937","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181890937?lang=zh_cn&edition=full","pubTime":"2026-08-12 09:37","pubTimestamp":1786498646,"startTime":"0","endTime":"0","summary":"亚盛医药将于2026年08月19日美股盘前发布最新季度财报，市场聚焦盈利改善节奏与商业化推进进度。市场一致预期显示，本季度亚盛医药营收预计为5,097.60万美元，同比增加58.18%；调整后每股收益预计为-0.26美元，同比改善73.17%；EBIT预计为-1.17亿美元，同比下降43.11%；由于缺乏公司端明确口径，毛利率与净利润或净利率的本季度量化指引未见披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656419833","title":"亚盛医药聘任CBO、CCO分管全球业务拓展及海外商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656419833","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656419833?lang=zh_cn&edition=full","pubTime":"2026-08-03 09:11","pubTimestamp":1785719460,"startTime":"0","endTime":"0","summary":"8月3日，亚盛医药（06855）发布公告，公司宣布两项高管任命，聘任FaialMiyara博士担任CBO统筹全球业务拓展，JimZiegler出任CCO，负责大中华区以外全球产品商业化运营，二人直接向董事长兼首席执行官杨大俊博士汇报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829261521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829261521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06855","BK4009","BK4139","LU2506951792.HKD","LU2357125470.USD","CCO","LU0823414551.USD","LU2249611893.SGD","AAPG","BK1161","LU0823414478.USD","LU2294711713.HKD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656845349","title":"亚盛医药任命首席业务拓展官和首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2656845349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656845349?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:25","pubTimestamp":1785716700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346342","title":"亚盛医药(06855)任命Faiçal Miyara博士为首席业务拓展官，任命Jim Ziegler为首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656346342?lang=zh_cn&edition=full","pubTime":"2026-08-03 07:37","pubTimestamp":1785713832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，公司任命Faial Miyara博士为首席业务拓展官，负责亚盛医药的全球业务拓展工作;并任命Jim Ziegler为首席商务运营官，负责公司产品在大中华地区以外的全球市场的商业化运营。Miyara博士和Ziegler先生直接向公司董事长兼首席执行官杨大俊博士汇报。Miyara博士在全球大型制药公司和生物技术公司中拥有超过20年的肿瘤领域商务拓展经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK4139","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654992650","title":"【祝贺】亚盛医药杨大俊荣登《The Medicine Maker》2026全球最具影响力人物榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2654992650","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654992650?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:26","pubTimestamp":1785119160,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年7月27日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司董事长兼首席执行官杨大俊博士荣登国际知名医药产业媒体《The Medicine Maker》2026年度\"The Power List\"，在小分子领域TOP10名单中位居第三位。《The Medicine Maker》是全球制药产业链极具影响力的专业媒体，聚焦药物研发、CMC 工艺开发、产业化落地与新药商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","BK4139","BK1574","BK1161","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647858376","title":"亚盛医药(06855)根据2021年受限制股份单位计划授出44.07万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2647858376","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647858376?lang=zh_cn&edition=full","pubTime":"2026-06-30 08:53","pubTimestamp":1782780809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，截至本公告日期，已根据2021年受限制股份单位计划向2021年受限制股份单位计划的453名获选人士授出44.07万份受限制股份单位，相当于44.07万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","06855","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2643228118","title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228118","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643228118?lang=zh_cn&edition=full","pubTime":"2026-06-15 07:29","pubTimestamp":1781479754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 公布，公司核心产品的17项临床进展已在2026年欧洲血液学协会年会上精彩亮相，其中包括8项壁报展示。2026年欧洲血液学协会 年会于2026年6月11日至2026年6月14日在瑞典斯德哥尔摩举办。利沙托克拉在髓系肿瘤的真实世界数据也为其临床价值提供了强有力的佐证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855","BK4139","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642287999","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642287999","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642287999?lang=zh_cn&edition=full","pubTime":"2026-06-11 21:31","pubTimestamp":1781184682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月11日，受托人就2022年受限制股份单位计划目的于场内购买合共11万股现有股份以在归属后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4139","BK1574","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642426730","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划购买19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426730","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642426730?lang=zh_cn&edition=full","pubTime":"2026-06-10 20:54","pubTimestamp":1781096082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月10日，受托人就2022年受限制股份单位计划目的于场内购买合共19万股现有股份以在归属后满足受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1574","AAPG","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937177","title":"国泰海通证券：首予亚盛医药(06855)“增持”评级 目标价59.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937177","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640937177?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:58","pubTimestamp":1780304322,"startTime":"0","endTime":"0","summary":"2025年，公司商业化成果显著，实现总收益5.74亿元，不考虑武田付款同比增长90%，其中，奥雷巴替尼实现收入4.35亿元，利沙托克拉实现7085万元，合计5.06亿元。2025年末现金余额为24.7亿元，现金储备稳健，可以支撑到2027年。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06855","AAPG","EWH","161027","02611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982786","title":"【直击ASCO 2026】亚盛医药MDM2-p53抑制剂APG-115儿童实体瘤数据首发，\"星光计划\"品种潜力初显","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982786","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640982786?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:40","pubTimestamp":1780278000,"startTime":"0","endTime":"0","summary":"此次快速口头报告的研究进展初步展现了APG-115在儿童相关实体瘤患者中的抗肿瘤活性和安全性。此次在ASCO 展示的数据证实，APG-115 单药及联合利沙托克拉展现出良好耐受性与显著抗肿瘤活性，尤其是CR 病例令人鼓舞。此次在ASCO展示的研究为APG-115治疗儿童实体瘤患者的数据首次亮相，初步展现的疗效和耐受性令人鼓舞。值得一提的是，APG-115此前已获CDE纳入'星光计划'，拟开发用于多种儿童实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","AAPG","LU2125909759.SGD","BK4139","BK1574","BK4129","APG","LU1923622291.USD","LU2125909916.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639645908","title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2639645908","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639645908?lang=zh_cn&edition=full","pubTime":"2026-05-29 11:23","pubTimestamp":1780025014,"startTime":"0","endTime":"0","summary":"财报显示，2025年，亚盛医药实现营业收入5.74亿元，且截至目前市值已超过百亿港元。而耐立克和利生妥两大十亿美元分子相继获批上市并在终端市场实现快速放量，便是亚盛医药能够顺利达成18A“摘B”里程碑的重要原因。智通财经APP了解到，亚盛医药今年六项重磅研究成果入选2026年ASCO年会。以上无疑都将成为亚盛医药年内的重要催化。近年来已有10数家18A企业顺利“摘B”，并在“摘B”后实现了可观的估值增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK1161","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638992766","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638992766","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638992766?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:58","pubTimestamp":1779976713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月28日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在归属后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","06855","AAPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651100","title":"亚盛医药获香港联交所批准从股票代码中移除\"B\"，6月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651100","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638651100?lang=zh_cn&edition=full","pubTime":"2026-05-28 11:06","pubTimestamp":1779937560,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年5月28日 /美通社/ --致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，因公司已符合香港联交所上市规则第8.05条的市值/收益要求，日前已获得香港联交所批准，将于2026年6月1日起正式将\"B\"标记从股票代码中移除。亚盛医药于2019年10月28日通过18A规则在香港联交所主板挂牌上市，后陆续纳入深港通和沪港通股票名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","06855","BK4139","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638081685","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买合共10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638081685","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638081685?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:58","pubTimestamp":1779890296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月27日，受托人就2022年受限制股份单位计划目的于场内购买合共10万股现有股份以在归属后满足受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","AAPG","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638501850","title":"亚盛医药-B(06855)：中英文简称将不再加上标记“B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2638501850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638501850?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:31","pubTimestamp":1779877916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，由于相关规则不适用，公司的中英文简称自2026年6月1日起将不再加上标记“B”。公司的股份将以新英文股份简称“ASCENTAGE”及中文股份简称“亚盛医药”在联交所买卖。公司的股份代号维持不变，仍为“6855”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1574","BK1161","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363327","title":"亚盛医药-B(06855)：于2026年美国临床肿瘤学会年上公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637363327?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:46","pubTimestamp":1779407170,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司六项入选2026年美国临床肿瘤学会年会的临床研究的摘要已于ASCO官网公布。本届ASCO年会将于2026年5月29日至2026年6月2日在芝加哥伊利诺伊州McCormick会议中心以线上线下结合的形式举办。该方案安全性可控，在儿童相关实体瘤中初步展现抗肿瘤活性，值得进一步研究。主要终点均为24周的主要分子学反应率。研究计划纳入约440例患者，在18个国家126个中心开展，目前正在招募中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1574","AAPG","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630353293","title":"亚盛医药Bcl-2抑制剂利生妥®获 2026 版 CSCO系列指南多项重磅推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353293","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630353293?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:49","pubTimestamp":1777254540,"startTime":"0","endTime":"0","summary":"利沙托克拉是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。作为中国首个获批上市的国产原创Bcl-2抑制剂，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展现了该产品在多个血液肿瘤领域的卓越临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B42XCP33.USD","LU0889566641.SGD","LU1778281490.HKD","LU1162221912.USD","SG9999001424.SGD","CSCO","LU0823417653.USD","LU1066051811.HKD","LU2286300806.USD","LU2237443622.USD","BK4579","LU0348723411.USD","IE00B3PB1722.GBP","BK4588","06855","BK1161","BK4585","LU0942090050.USD","LU1674673691.USD","AAPG","SG9999015945.SGD","BK4020","BK4560","LU1066053197.SGD","LU2237443895.HKD","LU1571399168.USD","LU1883839398.USD","SG9999002224.SGD","LU1059921491.USD","LU1221951129.SGD","LU2237443465.HKD","IE00BSNM7G36.USD","IE000M9KFDE8.USD","LU0234570918.USD","LU1032955483.USD","LU1244550577.SGD","CSCL","BK4533","BK1574","SG9999015986.USD","IE00BVYPNV92.GBP","LU1267930813.SGD","LU0868494708.USD","LU2247934214.USD","LU0234572021.USD","LU0203345920.USD","LU2102340556.USD","LU0203347892.USD","LU1066051498.USD","CSCS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":-0.0731},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0093},{"period":"6month","weight":-0.2498},{"period":"1year","weight":-0.5798},{"period":"ytd","weight":-0.3384}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤治疗药物发现、研发及商业化的控股公司。该公司主营业务是从事开发及销售针对肿瘤、乙肝及老化相关的疾病的新型小规模疗法。该公司的主要产品包括Olverembatinib（HQP1351）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918等产品。该公司的产品主要用于治疗主要血液系统恶性肿瘤，包括慢性粒细胞白血病、急性粒细胞白血病、慢性淋巴细胞白血病、急性淋巴细胞白血病、骨髓增生异常综合症及多发性骨髓瘤。该公司主要在国内市场开展业务。","exchange":"NASDAQ","name":"亚盛医药","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,AAPG,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}